1(CMS) Centers for Medicare & Medicaid Services, web site, Washington, DC. 被引量：1
2Eisenberg, Rebecca S., 2001, "The Shifting Functional Balance of Patents and Drug Regulation," Health Affairs, September/October. 被引量：1
3Falland, Sherman, Goodman, Alien C., and Stano, Miron, 2003, The Economics of Health and Health Care, Fourth Edition, Pearson Prentice Hall. 被引量：1
4Families USA, 2003, Out-Of-Bounds : Rising Prescription Drug Prices for Seniors, Washington DC, July. 被引量：1
5(FDA) U.S. Food and Drug Administration, 2003, "FDA's Drug Review and Approval Time, FDA web site. 被引量：1
6(FDA) U.S. Food and Drug Administration, 2002, "FDA and the Drug Development Process: How the Agency Ensures that Drugs are Safe and Effective," FDA Just the Facts, Publication No. FS 02-5, February. 被引量：1
7(FDA) U.S. Food and Drug Administration, 2003, "FDA Generic Drugs Final Rule and Initiative,"FDA web site, June 12. 被引量：1
8(FDA) U.S. Food and Drag Administration, 1999, From Test Tube to Patient: Improving Health through Human Drugs, September. 被引量：1
9(Frc) U.S. Federal Trade Commission, 2002, Generic Drug Entry Prior to Patent Expiration: An FTC Study, Washington DC, July. 被引量：1
10(Kaiser) The Kaiser Family Foundation, 2001, Prescription Drug Trends : A Chartbook Update, November. 被引量：1
